A novel approach for ex-vivo expansion (EvE) of NK CD3−/CD16+/56+bright/dim subsets expressing increased inhibitory receptors from cryopreserved/thawed/expanded/recryopreserved/rethawed (CTECT) and cryopreserved/thawed/recryopreserved/rethawed/expanded (CTCTE) umbilical cord blood (UCB) using anti-CD3, IL-2, IL-7 and IL-12 (AB/CY)  by Ayello, J. et al.
should be discontinued, and calculations individualized for each
procedure.
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A NOVEL APPROACH FOR EX-VIVO EXPANSION (EVE) OF NK CD3-/
CD16/56BRIGHT/DIM SUBSETS EXPRESSING INCREASED INHIBITORY
RECEPTORS FROM CRYOPRESERVED/THAWED/EXPANDED/RECRYO-
PRESERVED/RETHAWED (CTECT) AND CRYOPRESERVED/THAWED/RE-
CRYOPRESERVED/RETHAWED/EXPANDED (CTCTE) UMBILICAL CORD
BLOOD (UCB) USING ANTI-CD3, IL-2, IL-7 AND IL-12 (AB/CY)
Ayello, J.1, Satwani, P.1, van de Ven, C.1, Simpson, L.L.1, Kurtzberg,
J.2, Cairo, M.S.1 1. Children’s Hospital of New York-Presbyterian,
Columbia University, New York, NY; 2. Duke University, Durham,
NC
CD56brightdimNK express killer-Ig-like receptors (KIR) and
C-lectin (NKG2), and natural cytoxicity receptors (NCR) involved
with tumor target recognition may play a role in ACI of malig-
nancies (Farag et al, Blood 100:1935, 2002). We compared expan-
sion, maturation and cell survival of CD3-/CD16/56,
CD56bright/dim, KIR inhibitory and C-lectin NK subsets in UCB
aliquots. Non-adherent cells were cultured in SF AIM-V alone or
with anti-CD3 (50 ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml) and
IL-12 (10 ng/ml) (AB/CY). The expanded population was analyzed
for expression of NK subsets (CD94, CD16, CD56bright/dim)
and NK receptors (KIR3DL1, KIR2DL1/S1, KIR2DL2 and
NKG2A) by ﬂow cytometry using CD16, CD56, NKBL1,
CD158a, CD158b, CD94 and NKG2A mAbs. Apoptotic markers
were determined by presence of Annexin V and PI. A signiﬁcant
increase in CD16/CD56bright /dim  and CD94/NKG2A ex-
pression was seen in CTECT and CTCTE in AB/CY compared to
AIM-V alone (CD16/56bright/CTECT: 11 1 vs 2.5 .3%, p
.05; CD16/CD56dim: 46  6 vs 27  2%, p  .03; CD16/
56bright/CTCTE: 9  2 vs 2  .2%, p  .05; CD16/CD56dim:
40  2 vs 27  3%, p  .01; CD94/NKG2A: CTECT: 17  3
vs 2  .9%, p  .001; CTCTE: 25  2 vs 8  3%, p  .001).
Signiﬁcant increases were seen in NK KIR receptors expression
(CD56bright/KIR3DL1 and CD56dim/KIR3DL1) when AB/CY
was compared to AIM-V (CTECT: 11  0.7 vs .4  .07%, p 
.0001; 4  0.1 vs 1.5  0.4%, p  .003; CTCTE: 7  2 vs 1  .3
%, p  .05; 8  1 vs 3  .8%, p  .01, respectively), CD56bright/
KIR2DL1/S1 and CD56dim/KIR2DL1/S1 (CTECT: 12  1 vs
3  .4%, p  .004; 41  2 vs 9  1%, p  .0002; CTCTE: 6 
.5 vs 2  .1%, p  .05; 22  8 vs 5  1, p  .01) and CD56bright/
KIR2DL2 and CD56dim/KIR2DL2 (CTECT: 14  .8 vs 2 
.2%, p  .0002 and 29  .9 vs 12  .4%, p  .0001; CTCTE:
14  2 vs 2  .1%, p  .05 and 25  7 vs 6  1%, p  .001,
respectively). To determine if the increase was secondary to in-
creased cell survival, CTECT and CTCTE AB/CY expanded
cultures showed minimal apoptosis compared to SF AIM-V (1.1 
3 vs 6 .5%, p .001; 5 1 vs 11 .6%, p .05). No signiﬁcant
difference between CTECT and CTCTE modalities was seen
except in CD94/NKG2A (p  .05) and CD56bright/KIR2DL2
(p  .05). These data suggest that CD16/CD56bright/dim NK
subsets expressing increased KIR and C-lectin receptors can be
EvE with AB/CY from CTECT or CTCTE UCB for possible use
in ACI for DLI after UCBT. In-vitro functional and in-vivo
xenotransplant animal studies are underway to further examine the
cytolytic activity of these UCB NK subsets.
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EX VIVO EXPANSION OF IMMATURE AND MATURE T CELLS DERIVED
FROM UMBILICAL CORD BLOOD (UCB)
Staba, S.L., Crapnell, K.B., Hall, J.G., Reese, M., Kurtzberg, J. Duke
University Medical Center, Durham, NC
Introduction: Unrelated umbilical cord blood (UCB) is an effec-
tive source of allogeneic hematopoietic stem cells for transplanta-
tion therapy in patients lacking matched bone marrow donors.
Opportunistic infection is the major cause of mortality post trans-
plant, due in part to the immunologic naivete´ of the UCB T-cells.
We hypothesized that UCB derived immature and mature T-cells
could be expanded ex-vivo, and utilized a patient-derived skin
stromal layer with a supplemental cytokine cocktail to support the
growth of bulk UCB cells. The long term goal is to provide
UCB-derived adoptive immunotherapy in UCBT recipients.
Methods: Patient derived skin ﬁbroblasts were cultured in a media
of IMDM, 10% fetal calf serum and 10% horse serum for 14 days,
then irradiated to 5,000 cGy. Cryopreserved UCB cells were
thawed and cultured on this stromal layer in the same media
supplemented with a cytokine cocktail of interleukin-7 (IL-7) (10
ng/ml), ﬂt-3 ligand (10 ng/ml), and stem cell factor (50 ng/ml).
UCB cells were cultured with cytokines alone and skin alone as
controls. As a 2nd phase, interleukin-2 (IL-2) was added at day 14
for further expansion, with cells cultured for an additional 14 days
thereafter. Cell count, viability, and FACs analysis were per-
formed. Results: Gating on CD3, in cells cultured with both
skin stroma and cytokines mean fold increases of 6 in CD4, 11 in
CD8 and 34 in CD4/CD8 cells were seen. With cytokines
alone, mean fold increases were 3, 4 and 10 respectively. Minimal
expansion occurred with skin alone. With cytokines and IL-2,
mean fold increases were 4 in CD4, 4 in CD8 and 10 in
CD4/CD8 cells. Maximal expansion occurred with skin
stroma, the cytokine cocktail and IL-2, with mean fold increases of
9 in CD4, 11 in CD8 and 53 in CD4/CD8 cells. Results are
summarized in the table below. Conclusions: The expansion of
T-cells from unfractionated, red blood cell depleted, cryopreserved
UCB can be accomplished using a cytokine cocktail of IL-7, Flt 3
ligand and SCF over a patient derived, irradiated skin stromal
layer. Maximal expansion occurs with the addition of IL-2 and was
greatest in the immature CD4/CD8T-cell subset. We hypoth-
esize that this subset of T cells could serve as a target population
for adoptive immunotherapy, however further testing will deter-
mine the optimal cellular target and conditions for ex vivo expan-
sion and immunization. These cells could then be used to augment
immune reconstitution after UCBT.
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ISOLATION AND FUNCTIONAL INHIBITORY AFFECTS OF SPECIFIC PEP-
TIDES BOUND TO TYPE 2 DENDRITIC CELLS (DC2)
Rosenthal, H.S., Jaye, D.L., Cherry, E., Waller, E.K. Emory Univer-
sity, Atlanta, GA
Introduction: The impact of immunoregulatory type 1 (DC1)
and type 2 (DC2) dendritic cells in allogeneic hematopoetic pro-
genitor cell (HPC) transplantation has increased in interest. We
have shown that greater numbers of DC2s in allogeneic HPC
transplanted grafts has resulted in an increase in post-transplant
relapse and a reduction of graft vs host disease (GVHD). Isolation
of dendritic cell speciﬁc peptides thru phage display technology
provides a method of studying the immunoregulatory affects of
these cells and perhaps engineer grafts with anti-tumor affects.
Method: Random phage peptide libraries were incubated over-
night at 4° C with column enriched peripheral blood DC2 cells.
Unbound phage was removed by washing. FACS sorting of the
Lin-, CD123, HLA-Dr cells, further puriﬁed the DC2 popu-
lation. DC2 bound phage were removed from the cell surface,
eluted and puriﬁed. Three rounds of this phage selection process
(panning) were performed. A portion of the round 2 phage puri-
ﬁcation was incubated with enriched monocytes prior to incuba-
tion with DC2 cells to assist in eliminating phage that recognized
common epitopes on both cell types. Flow cytometry identiﬁed
individual phage clones isolated from plaque assays that were
Table.
Conditions
Mean Fold Expansion
CD4 CD8 CD4/CD8
Skin Alone (n  8) 0 0 0
Cytokines (n  10) 3 4 10
Cytokines  IL-2 (n  5) 4 4 10
Skin  Cytokines (n  10) 6 11 34
Skin  Cytokines  IL-2 (n  5) 9 12 53
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